| 書目名稱 | Fluoropyrimidines in Cancer Therapy |
| 編輯 | Youcef M. Rustum |
| 視頻video | http://file.papertrans.cn/345/344752/344752.mp4 |
| 概述 | Includes supplementary material: |
| 叢書名稱 | Cancer Drug Discovery and Development |
| 圖書封面 |  |
| 描述 | Leading cancer researchers update and review the mechanisms of action and the therapeutic selectivity and efficacy of 5-FU with and without leucovorin and its prodrugs in the treatment of colorectal cancer. Among the combination agents considered are UFT/LV, 5-FU/EU, capecitabine (Xeloda), S-1, and a variety of thymidylate synthase inhibitors. The authors discuss the potential advantages and disadvantages of these varied drugs and their mode of administration. Based on historical results with these agents when used alone, they also present a rationale for their results when used in combination with other agents. |
| 出版日期 | Book 2003 |
| 關(guān)鍵詞 | cell; clinical trial; liver; metastasis; pharmacology |
| 版次 | 1 |
| doi | https://doi.org/10.1007/978-1-59259-337-8 |
| isbn_softcover | 978-1-61737-274-2 |
| isbn_ebook | 978-1-59259-337-8Series ISSN 2196-9906 Series E-ISSN 2196-9914 |
| issn_series | 2196-9906 |
| copyright | Springer Science+Business Media New York 2003 |
|Archiver|手機版|小黑屋|
派博傳思國際
( 京公網(wǎng)安備110108008328)
GMT+8, 2025-10-11 11:04
發(fā)表于 2025-3-21 17:19:47
